Alexandra Langlais

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016 · 969 citations · Full text

Advanced Lung Disease, Medicine, Pathology +8

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette et al. · Journal of Thoracic Oncology · 2019 · 181 citations · Full text

Medicine, Pharmacology, Pathology +8

Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i>-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

M. Duruisseaux, Benjamin Besse, J. Cadranel et al. · Oncotarget · 2017 · 160 citations · Full text

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazières, A. Lavolé et al. · Journal for ImmunoTherapy of Cancer · 2022 · 108 citations · Full text

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Jean-Louis Pujol, A. Lavolé, Élisabeth Quoix et al. · Annals of Oncology · 2015 · 95 citations · Full text

Ifct-0802 Trial, Medicine, Metronomic Therapy +7